



Major Summary and Market Trends for 2022

Longevity Clinics Active in 2022




The global market includes more than 1,000 companies that provide anti-ageing medical service in more than 30 countries. The USA is the largest region for the anti-ageing medicine market. The dominance of the USA in the global market can be attributed to an increasing number of regulatory approvals for customised medicine, as well as increased acceptance of new medical approaches as diagnostic, procedures and therapeutic agents.

Proportion of Medical Companies by Type of Service




More than 65% of global companies produce medical devices and provide AI-based platforms for telehealth medicine, diagnostic, and patient treatment. Personalised medicine and companies that provide treatment and diagnosis of cardiovascular disorders share ~13% and 12% respectively. This proportion is more or less the same in local markets. Except the African region where Cardiovascular Medicine dominates with 40% of market share.


Longevity Medicine Framework




2020: 58 Devices Cleared or Approved by FDA



2021: 25 Devices Cleared or Approved by FDA




Non-Cancer RMAT Designation Requests Received in 2017-2022




In Q1 2022, the total number of requests for registration of Regenerative Medicine Advanced Treatment (RMAT) products (non-cancer) was 14 applications. During this period more than half of applications were granted (62.5%, 5 applications). Three applications denied (37.5%) and no withdrawal applications.

Non-Cancer RMAT Designation Requests: Distribution by Specialty, 2017-2022



In 2017-2022, the highest number of designation requests were presented for the following categories: Neurology (26.9%), Cardiovascular Disorders (19.2%) and Orthopaedic Disorders (11.2%). Other categories are less than 10% from the total number of applications.

Distribution of non-Cancer RMAT Approved by Region



Recent advances in understanding the molecular mechanism of human diseases and treatment are boosting the global advanced therapy market. This market is categorised into tissue regeneration after chemotherapy, neurological diseases, rare genetic diseases and cardiovascular disorders. Monogenic diseases had the highest market share in recent years. Viral vectors (mainly adeno-associated virus, retrovirus, lentivirus), in comparison to non-viral vectors, are the preferred gene therapy vehicles in the clinic. North America and Europe are the dominant players and drive advances in the market of non-cancer and rare genetic diseases. However, safety and efficacy problems, prolonged laboratory procedures for conducting clinical studies, unknown product interactions with the host, and the high cost of RMAT are major barriers in the way of the advanced therapy market.